Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Penel

Showing results (31-40 of 350) with videos related to

Pageof 35
Sort By:
Current Treatment Options in Oncology|December 11, 2007
Angiosarcomas and taxanesNicolas Penel, Amélie Lansiaux, Antoine Adenis
Cancer|August 9, 2020
Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signalsNicolas Penel, Thomas Ryckewaert, Diane Pannier
Current Opinion in Oncology|March 16, 2012
A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trialsSophie Cousin, Sophie Taieb, Nicolas Penel
Current Opinion in Oncology|March 3, 2015
Metabolic disorders associated with the use of targeted cancer therapiesNuria Kotecki, Nicolas Penel, Ahmad Awada
Current Opinion in Oncology|July 19, 2018
Reappraisal of eligibility criteria in cancer clinical trialsNicolas Penel, Loïc Lebellec, Marie Vanseymortier
Current Opinion in Oncology|July 14, 2017
How to emerge from the conservatism in clinical research methodology?Nuria Kotecki, Nicolas Penel, Ahmad Awada
Case Reports in Oncology|May 8, 2014
Tumor calcification: a new response pattern of myxoid liposarcoma to trabectedinAnthony Turpin, Sophie Taieb, Nicolas Penel
La Revue Du Praticien|January 23, 2026
[Sarcoma: a plural entity]Thibaud Valentin, Nicolas Penel, Maud Toulmonde
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 15, 2020
Switch in use of midazolam for cancer patients during the COVID-19 pandemicGuillaume Marliot, Nicolas Penel, Vincent Gamblin
Bulletin Du Cancer|September 20, 2015
[Soft tissue sarcomas: Questions about reported clinical benefit]Nicolas Penel, Sophie Cousin, Nuria Kotecki
Pageof 35

Showing results (31-40 of 350) with videos related to

Sort By:
Pageof 35
Current Treatment Options in Oncology|December 11, 2007
Angiosarcomas and taxanesNicolas Penel, Amélie Lansiaux, Antoine Adenis
Cancer|August 9, 2020
Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signalsNicolas Penel, Thomas Ryckewaert, Diane Pannier
Current Opinion in Oncology|March 16, 2012
A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trialsSophie Cousin, Sophie Taieb, Nicolas Penel
Current Opinion in Oncology|March 3, 2015
Metabolic disorders associated with the use of targeted cancer therapiesNuria Kotecki, Nicolas Penel, Ahmad Awada
Current Opinion in Oncology|July 19, 2018
Reappraisal of eligibility criteria in cancer clinical trialsNicolas Penel, Loïc Lebellec, Marie Vanseymortier
Current Opinion in Oncology|July 14, 2017
How to emerge from the conservatism in clinical research methodology?Nuria Kotecki, Nicolas Penel, Ahmad Awada
Case Reports in Oncology|May 8, 2014
Tumor calcification: a new response pattern of myxoid liposarcoma to trabectedinAnthony Turpin, Sophie Taieb, Nicolas Penel
La Revue Du Praticien|January 23, 2026
[Sarcoma: a plural entity]Thibaud Valentin, Nicolas Penel, Maud Toulmonde
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 15, 2020
Switch in use of midazolam for cancer patients during the COVID-19 pandemicGuillaume Marliot, Nicolas Penel, Vincent Gamblin
Bulletin Du Cancer|September 20, 2015
[Soft tissue sarcomas: Questions about reported clinical benefit]Nicolas Penel, Sophie Cousin, Nuria Kotecki
Pageof 35